Rubric Capital Reports 5.51% Passive Stake In ADMA Biologics, With Shared Voting Authority
The investment adviser and David Rosen reported the same fund-held shares, with no purpose of changing ADMA's control.
Rubric Capital Management reported a 5.51% passive stake in ADMA Biologics, which makes plasma-derived medicines for people with weakened immune systems. Its SEC ownership disclosure filed Monday covered 12,352,584 common shares held by funds and accounts it advises as of September 30.
One Holding, Shared Voting Power
David Rosen, managing member of Rubric Capital Management GP, the investment adviser's general partner, reported shared voting authority over the same shares. Rubric and Rosen each listed the identical holding; the reports describe one pool of fund-held stock.
Rubric Capital Master Fund LP, one of the advised funds, has rights to dividends or sale proceeds tied to more than 5% of ADMA's common stock. That identifies the fund with the economic rights, distinct from the adviser and Rosen's shared voting authority.
The reporting persons certified that the shares were bought and are held as part of ordinary business activity, without a purpose of changing or influencing ADMA's control.
The reported percentage uses ADMA's 223,984,680 common shares outstanding on July 31. ADMA reported that share count in its second-quarter report filed August 5.
Plasma Medicines And Collection Centers
ADMA's medicines serve people whose weakened immune systems leave them vulnerable to infection. Its FDA-approved products include ASCENIV and BIVIGAM, intravenous immune globulins used for primary immunodeficiency, and Nabi-HB, used after acute exposure to hepatitis B.
Physician specialists use the products, which national distributors supply to home infusion providers, hospitals and clinics. ADMA BioManufacturing makes them at the company's Boca Raton, Florida plant.
Its Plasma Collection Centers business supplies plasma for those medicines and sells remaining plasma to outside customers. ADMA operated ten FDA-licensed U.S. plasma collection centers as of December 31, 2025.
ADMA's market value was $3.0 billion in Monday's original report, as of 4:49 p.m. ET.
A New Jersey Derivative Case
ADMA was also listed in ES Trust v. Grossman, a New Jersey case dated September 2 and classified as derivative litigation—litigation brought on a company's behalf. The securities-and-commodities case is before Judge Esther Salas.
Sources
- SCHEDULE 13G — Rubric Capital Management LP re: ADMA Biologics, Inc. (ADMA) — SEC EDGAR
- ES TRUST v. GROSSMAN et al — law360.com